Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

Endocrinology

Volumn 146, Issue 3, 2005, Pages 1226-1235

  Ali, A Afshan ^a   Weinstein, Robert S ^a   Stewart, Scott A ^a   Parfitt, A Michael ^a   Manolagas, Stavros C ^a   Jilka, Robert L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SIALOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADIPOCYTE; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITOMETRY; CANCELLOUS BONE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; MALE; MESENCHYMAL STEM CELL; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ADIPOCYTES; AGING; ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; DENSITOMETRY; FATTY ACIDS; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIGANDS; MESODERM; MICE; OSTEOBLASTS; OSTEOPOROSIS; PPAR GAMMA; STEM CELLS; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 14244250617     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0735     Document Type: Article

References (53)

1. Aubin JE, Triffitt JT 2002 Mesenchymal stem cells and osteoblast differentiation. In: Bilezikian JP, Raisz LG, Rodan G, eds. Principles of bone biology. 2nd ed. San Diego: Academic Press; 59-81
2. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M 2001 Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165-171
3. Kajkenova O, Lecka-Czernik B, Gubrij I, Hauser SP, Takahashi K, Parfitt AM, Jilka RL, Manolagas SC, Lipschitz DA 1997 Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12:1772-1779
4. Meunier P, Aaron J, Edouard C, Vignon G 1971 Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orth Rel Res 80:147-154
5. Lips P, Courpron P, Meunier PJ 1978 Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13-17
6. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G 1999 A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 13:1025-1036
7. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, De Crombrugghe B 2002 The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29
8. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 16:27-32
9. Yki-Jarvinen H 2004 Thiazolidinediones. N Engl J Med 351:1106-1118
10. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
11. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM,Lenhard JM, Lehmann JM 1997 Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94:4318-4323
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
13. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
14. Nosjean O, Boulin JA 2002 Natural ligands of PPARγ: are prostaglandin J(2) derivatives really playing the part? Cell Signal 14:573-583
15. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK 1999 Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382
16. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung Ui, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855
17. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 74:357-371
18. Jennermann C, Triantafillou J, Cowan D, Pennink BGA, Connolly KM, Morris DC 1995 Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 10:S241 (Abstract)
19. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
20. Fickavance LC, Buckingham RE, Wilding JP 2001 Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obes Metab 3:171-180
21. De VF, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J 1996 Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98:1004-1009
22. Cantello BC, Cawthorne MA, Cottam GF, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL 1994 [[ω-(Heterocyclylamino)alkoxy]benzyl] -2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985
23. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC 1996 Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740
24. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL 2003 Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272
25. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282
26. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1997 The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology 138:4013-4021
27. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
28. Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC 2004 The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145:1980-1987
29. Fu Q, Jilka RL, Manolagas SC, O'Brien CA 2002 Parathyroid hormone stimulates receptor activator of NFκB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875
30. Di Gregorio GB, Yamamoto M, Ali AA, Abe E, Roberson P, Manolagas SC, Jilka RL 2001 Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17α-estradiol. J Clin Invest 107:803-812
31. Jilka RL 1986 Parathyroid hormone-stimulated development of osteoclasts in cultures of cells from neonatal murine calvaria. Bone 7:29-40
32. Kuehl RO 2000 Design of experiments: statistical principles of research design and analysis. New York: Duxbury; 492-519
33. Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA 1996 Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J Biol Chem 271:29909-29914
34. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M 1996 Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76:593-629
35. Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM 2002 Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms. J Biol Chem 277:41925-41930
36. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA 2000 Inhibition of adipogenesis by Wnt signaling. Science 289:950-953
37. Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS, Shea M, Waters RV, Belknap JK, Peltz G, Orwoll ES 2004 Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303:229-232
38. Spiteller G 2000 Peroxidation of linoleic acid and its relation to aging and age dependent diseases. Ageing Res Rev 122:617-657
39. Kveiborg M, Sabatakos G, Chiusaroli R, Wu M, Philbrick WM, Horne WC, Baron R 2004 ΔFosB Induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. Mol Cell Biol 24:2820-2830
40. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanism of bone loss. J Clin Invest 72:1396-1409
41. Parfitt AM 1988 Bone remodeling: relationship to the amount and structure of bone and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ, eds. Osteoporosis - etiology, diagnosis and management. New York: Raven Press; 45-94
42. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR 2000 Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation. J Biol Chem 275:14388-14393
43. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y 1999 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065
44. Fu M, Zhang J, Lin Y, Zhu X, Willson TM, Chen YE 2002 Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 294:597-601
45. Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A 1999 Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801
46. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171
47. Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, Prior JC, Pickard L, Murray TM, Anastassiades T, Kirkland S, Joyce C, Joseph L, Papaioannou A, Jackson SA, Poliquin S, Adachi JD 2003 Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 18:784-790
48. Stolk RP, van Daele PL, Pols HA, Burger H, Hofman A, Birkenhager JC, Lamberts SW, Grobbee DE 1996 Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone [Erratum (1996) 19:566] 18:545-549
49. Lunt M, Masaryk P, Scheidt-Nave C, Nijs J, Poor G, Pols H, Falch JA, Hammermeister G, Reid DM, Benevolenskaya L, Weber K, Cannata J, O'Neill TW, Felsenberg D, Silman AJ, Reeve J 2001 The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int 12:688-698
50. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM 1995 Bone loss and bone turnover in diabetes. Diabetes 44:775-782
51. Barish GD, Evans RM 2004 PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158-165
52. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V 2004 Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246-4253
53. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216